{"FP": [{"generated": ["rhabdomyolysis", "heavy toxicity", "retroperitoneal liposarcoma"], "gold": ["rhabdomyolysis", "adverse event", "retroperitoneal liposarcoma"], "text": "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event."}, {"generated": ["abdominal mass"], "gold": [], "text": "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection."}, {"generated": ["lesion progressed rapidly", "retro-peritoneum space", "16 \u00d7 10 cm"], "gold": [], "text": "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space."}, {"generated": ["lesion progressed rapidly", "retro-peritoneum space", "16 \u00d7 10 cm"], "gold": [], "text": "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space."}, {"generated": ["lesion progressed rapidly", "retro-peritoneum space", "16 \u00d7 10 cm"], "gold": [], "text": "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space."}, {"generated": ["absence of co-morbidity"], "gold": [], "text": "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin."}, {"generated": ["activation of the death receptor", "inhibition of transport mechanisms"], "gold": [], "text": "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms."}, {"generated": ["activation of the death receptor", "inhibition of transport mechanisms"], "gold": [], "text": "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms."}, {"generated": ["medicinal cannabis", "health risks"], "gold": [], "text": "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use."}, {"generated": ["medicinal cannabis", "health risks"], "gold": [], "text": "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use."}, {"generated": ["Parkinson's disease (PD)"], "gold": ["PD"], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": ["genotype", "PGx results", "higher levels of dopamine", "COMT Met/Met"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["genotype", "PGx results", "higher levels of dopamine", "COMT Met/Met"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["genotype", "PGx results", "higher levels of dopamine", "COMT Met/Met"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["genotype", "PGx results", "higher levels of dopamine", "COMT Met/Met"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["range", "29% to 83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["range", "29% to 83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["very narrow therapeutic indices"], "gold": [], "text": "An important fact is that most of these affected drugs have very narrow therapeutic indices."}, {"generated": ["increasing number of studies"], "gold": [], "text": "To date an increasing number of studies in evaluating HDIs have been reported [11]."}, {"generated": ["HDIs", "herb products"], "gold": [], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": ["HDIs", "herb products"], "gold": [], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": ["hypoglycemic effect"], "gold": ["hypoglycemic"], "text": "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043)."}, {"generated": ["traditional hypoglycemic herbs"], "gold": ["hypoglycemic"], "text": "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs."}, {"generated": ["chronic use", "deleterious"], "gold": [], "text": "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier."}, {"generated": ["chronic use", "deleterious"], "gold": [], "text": "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier."}, {"generated": ["indigenous mode of extraction"], "gold": [], "text": "Extraction was performed using water to mimic the indigenous mode of extraction."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["pharmacodynamics", "drug-induced diseases", "adverse drug reactions", "drug-drug interactions", "pharmacotherapy", "drug-related toxicities", "drug-disease interactions", "pathology", "pharmacology", "pharmacokinetics", "drug-food interactions", "drug-nutrient interactions", "drug-genetic interactions"], "gold": [], "text": "[44]."}, {"generated": ["Drug-Drug Interaction (DDI)", "in vitro-in vivo-extrapolation (IVIVE)"], "gold": [], "text": "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug."}, {"generated": ["Drug-Drug Interaction (DDI)", "in vitro-in vivo-extrapolation (IVIVE)"], "gold": [], "text": "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug."}, {"generated": ["diabetic patients"], "gold": ["diabetic"], "text": "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001)."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "Elliot et al."}, {"generated": ["grapefruit", "gliclazide", "caffeine-containing beverages"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["grapefruit", "gliclazide", "caffeine-containing beverages"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["grapefruit", "gliclazide", "caffeine-containing beverages"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["pharmacology"], "gold": [], "text": "(2003)."}, {"generated": ["CL/Fs of glipizide", "CL/Fs of tolbutamide"], "gold": [], "text": "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively."}, {"generated": ["CL/Fs of glipizide", "CL/Fs of tolbutamide"], "gold": [], "text": "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively."}, {"generated": ["No specific pathologies or side effects mentioned in the provided text"], "gold": [], "text": "Park et al."}, {"generated": ["Epstein Barr virus (EBV)", "acute cytomegalovirus (CMV)"], "gold": ["Epstein Barr virus (EBV", "acute cytomegalovirus (CMV"], "text": "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative."}, {"generated": ["Epstein Barr virus (EBV)", "acute cytomegalovirus (CMV)"], "gold": ["Epstein Barr virus (EBV", "acute cytomegalovirus (CMV"], "text": "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative."}, {"generated": ["Antinuclear antibody (ANA)", "smooth muscle antibody"], "gold": [], "text": "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80."}, {"generated": ["Antinuclear antibody (ANA)", "smooth muscle antibody"], "gold": [], "text": "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80."}, {"generated": ["fibroinflammatory expansion of portal tracts", "plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "cholangiolar proliferation", "chronic hepatitis"], "gold": ["interface hepatitis", "chronic hepatitis"], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["fibroinflammatory expansion of portal tracts", "plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "cholangiolar proliferation", "chronic hepatitis"], "gold": ["interface hepatitis", "chronic hepatitis"], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["fibroinflammatory expansion of portal tracts", "plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "cholangiolar proliferation", "chronic hepatitis"], "gold": ["interface hepatitis", "chronic hepatitis"], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["fibroinflammatory expansion of portal tracts", "plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "cholangiolar proliferation", "chronic hepatitis"], "gold": ["interface hepatitis", "chronic hepatitis"], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["clinicopathological features"], "gold": [], "text": "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3."}, {"generated": ["autoimmune response"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["black cohosh hepatotoxicity"], "gold": ["hepatotoxicity"], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": ["bacterial infections"], "gold": [], "text": "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8]."}, {"generated": ["Group one"], "gold": [], "text": "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD)."}, {"generated": ["current studies at the pharmacokinetic level"], "gold": [], "text": "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["monkeypox", "swollen lymph nodes", "Kyasanur Forest disease", "fatigue", "fever", "headache", "pustules", "body aches", "rash"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["digoxin"], "gold": [], "text": "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates."}, {"generated": ["P-gp inhibition", "calcein-AM", "digoxin"], "gold": [], "text": "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006)."}, {"generated": ["P-gp inhibition", "calcein-AM", "digoxin"], "gold": [], "text": "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006)."}, {"generated": ["P-gp inhibition", "calcein-AM", "digoxin"], "gold": [], "text": "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006)."}, {"generated": ["pharmacology"], "gold": [], "text": "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests."}, {"generated": ["inhibitory effects on the respective enzymes"], "gold": [], "text": "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c)."}, {"generated": ["CYP3A4 inhibitor", "CYP2C9 inhibitor", "CYP2C8 inhibitor"], "gold": [], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": ["CYP3A4 inhibitor", "CYP2C9 inhibitor", "CYP2C8 inhibitor"], "gold": [], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": ["CYP3A4 inhibitor", "CYP2C9 inhibitor", "CYP2C8 inhibitor"], "gold": [], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "2)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "2)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "2)."}, {"generated": ["statistically not significant"], "gold": [], "text": "This result was statistically not significant."}, {"generated": ["grade 3 and 4 toxicities"], "gold": ["toxicities", "Adverse Events", "Cancer"], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["docetaxel"], "gold": [], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": ["alkylamides", "contents of DTAI", "midazolam studies"], "gold": [], "text": "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified."}, {"generated": ["alkylamides", "contents of DTAI", "midazolam studies"], "gold": [], "text": "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified."}, {"generated": ["alkylamides", "contents of DTAI", "midazolam studies"], "gold": [], "text": "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified."}, {"generated": ["pharmacokinetics of docetaxel"], "gold": [], "text": "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel."}, {"generated": ["CYP3A4-mediated interactions"], "gold": [], "text": "Thus, the risk of CYP3A4-mediated interactions may be product dependent."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["Rat"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["Rat"], "gold": [], "text": "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats."}, {"generated": ["red ginseng extract"], "gold": [], "text": "Sample Availability: Red ginseng extract are available from the authors."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "Conceptualization, M.-K.C."}, {"generated": ["Tubular Epithelial Damage", "Renal Glomerular Epithelial Dysfunction", "Renal Tubular Epithelial Damage", "Glomerular Basement Membrane Alterations", "Renal Tubular Dysfunction"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["Tubular Epithelial Damage", "Renal Glomerular Epithelial Dysfunction", "Renal Tubular Epithelial Damage", "Glomerular Basement Membrane Alterations", "Renal Tubular Dysfunction"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["Tubular Epithelial Damage", "Renal Glomerular Epithelial Dysfunction", "Renal Tubular Epithelial Damage", "Glomerular Basement Membrane Alterations", "Renal Tubular Dysfunction"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["Tubular Epithelial Damage", "Renal Glomerular Epithelial Dysfunction", "Renal Tubular Epithelial Damage", "Glomerular Basement Membrane Alterations", "Renal Tubular Dysfunction"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["Tubular Epithelial Damage", "Renal Glomerular Epithelial Dysfunction", "Renal Tubular Epithelial Damage", "Glomerular Basement Membrane Alterations", "Renal Tubular Dysfunction"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["2016; Bautista et al."], "gold": [], "text": "2016; Bautista et\u00a0al."}, {"generated": ["2014; Dybro et al."], "gold": [], "text": "2014; Dybro et\u00a0al."}, {"generated": ["interaction between AC and DST"], "gold": [], "text": "However, it is unknown whether there is an interaction between AC and DST."}, {"generated": ["3.5 \u03bcm"], "gold": [], "text": "; 3.5\u2009\u03bcm) at room temperature."}, {"generated": ["side effects", "pharmacology"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["side effects", "pharmacology"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["large individual differences in the effects of the drug"], "gold": [], "text": "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed."}, {"generated": ["controversial", "side effects", "further in-depth studies"], "gold": [], "text": "The results of existing studies are controversial and further in-depth studies are required."}, {"generated": ["controversial", "side effects", "further in-depth studies"], "gold": [], "text": "The results of existing studies are controversial and further in-depth studies are required."}, {"generated": ["controversial", "side effects", "further in-depth studies"], "gold": [], "text": "The results of existing studies are controversial and further in-depth studies are required."}, {"generated": ["combinations with Western drugs"], "gold": [], "text": "Most of these reports and studies are on combinations with Western drugs."}, {"generated": ["elevated or false-positive digoxin plasma concentration monitoring results"], "gold": ["renal dysfunction", "patients"], "text": "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results."}, {"generated": ["digoxin"], "gold": [], "text": "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "Li Xin et al."}, {"generated": ["ventricular tachycardia", "ventricular fibrillation", "arrhythmia", "ventricular precontraction"], "gold": ["arrhythmias", "arrhythmia", "ventricular precontraction, ventricular tachycardia,", "ventricular arrhythmias", "ventricular fibrillation"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["ventricular tachycardia", "ventricular fibrillation", "arrhythmia", "ventricular precontraction"], "gold": ["arrhythmias", "arrhythmia", "ventricular precontraction, ventricular tachycardia,", "ventricular arrhythmias", "ventricular fibrillation"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["imbalance of qi, blood, yin and yang"], "gold": [], "text": "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021)."}, {"generated": ["digoxin"], "gold": [], "text": "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations."}, {"generated": ["digoxin"], "gold": [], "text": "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians."}, {"generated": ["C. asiatica"], "gold": [], "text": "C. asiatica Plant Material and Preparation of CAW-R61J."}, {"generated": ["pharmacology"], "gold": [], "text": "Unless otherwise specified, all results were expressed as the means \u00b1 S.D."}, {"generated": ["percentage control value"], "gold": [], "text": "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "2 above (substituting logEC50 for logIC50)."}, {"generated": ["Prism 8.0.2", "curve fitting"], "gold": [], "text": "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA)."}, {"generated": ["Prism 8.0.2", "curve fitting"], "gold": [], "text": "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA)."}, {"generated": ["Not specified in the provided text"], "gold": [], "text": "Object name is dmd.120.090860f1.jpg Fig."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["side effects", "drug-induced conditions", "pathology", "toxic effects", "adverse effects"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["no specific pathologies or side effects mentioned"], "gold": [], "text": "***P < 0.0001."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "; data not shown)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "; data not shown)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "; data not shown)."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["Not specified in the provided text"], "gold": [], "text": "Object name is dmd.120.090860f3.jpg Fig."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["triplicate determinations"], "gold": [], "text": "of triplicate determinations."}, {"generated": ["CA derivatives"], "gold": [], "text": "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes."}, {"generated": ["product ion mass spectra", "previous reports", "mass fragmentation patterns"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["product ion mass spectra", "previous reports", "mass fragmentation patterns"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["product ion mass spectra", "previous reports", "mass fragmentation patterns"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["M.P."], "gold": [], "text": "and M.P."}, {"generated": ["chronic nature of HAART administration"], "gold": [], "text": "However, there are several challenges associated with the chronic nature of HAART administration."}, {"generated": ["improvement of the quality of life for people taking ART"], "gold": [], "text": "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2]."}, {"generated": ["no specific pathologies or side effects mentioned in the text provided"], "gold": [], "text": "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented."}, {"generated": ["GGT"], "gold": [], "text": "Therefore, we applied this dose of GGT in our study."}, {"generated": ["1000 mg", "GGT (7680 mg)", "AAP at 1000 once a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["1000 mg", "GGT (7680 mg)", "AAP at 1000 once a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["1000 mg", "GGT (7680 mg)", "AAP at 1000 once a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["J.-w.C.", "modeling", "Q.T.T.", "H.-y.Y.", "H.-m.B.", "L.T.N."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "modeling", "Q.T.T.", "H.-y.Y.", "H.-m.B.", "L.T.N."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "modeling", "Q.T.T.", "H.-y.Y.", "H.-m.B.", "L.T.N."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "modeling", "Q.T.T.", "H.-y.Y.", "H.-m.B.", "L.T.N."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "modeling", "Q.T.T.", "H.-y.Y.", "H.-m.B.", "L.T.N."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "modeling", "Q.T.T.", "H.-y.Y.", "H.-m.B.", "L.T.N."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["patients taking prescription medications"], "gold": [], "text": "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age."}, {"generated": ["age-related changes"], "gold": [], "text": "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly."}, {"generated": ["probe drug administration", "adherence"], "gold": [], "text": "Adherence to these restrictions was further emphasized five days before each probe drug administration."}, {"generated": ["probe drug administration", "adherence"], "gold": [], "text": "Adherence to these restrictions was further emphasized five days before each probe drug administration."}, {"generated": ["no serious adverse events"], "gold": [], "text": "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation."}, {"generated": ["95% confidence intervals", "phenotypic ratios"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["95% confidence intervals", "phenotypic ratios"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["St. John\u2019s wort"], "gold": [], "text": "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance."}, {"generated": ["earlier study", "young individuals"], "gold": [], "text": "This finding also corroborates the results of an earlier study in young individuals."}, {"generated": ["earlier study", "young individuals"], "gold": [], "text": "This finding also corroborates the results of an earlier study in young individuals."}, {"generated": ["St. John\u2019s wort"], "gold": [], "text": "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort."}, {"generated": ["elderly patients", "anticoagulant therapy"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["elderly patients", "anticoagulant therapy"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["platelet activating factor"], "gold": [], "text": "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides."}, {"generated": ["herb-drug interactions"], "gold": [], "text": "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms."}, {"generated": ["specific CYP isoforms"], "gold": [], "text": "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study."}, {"generated": ["plasma quinine", "3-hydroxyquinine"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "3-hydroxyquinine"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["adverse side effects from taking G. kola seeds"], "gold": ["Pregnancy", "hypersensitivity", "adverse side effects", "breastfeeding"], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["quinine sulphate tablets", "overnight fast"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["quinine sulphate tablets", "overnight fast"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["3-hydroxyquinine"], "gold": [], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": ["reduced AUC0\u2013\u221e of quinine"], "gold": [], "text": "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %."}, {"generated": ["dizziness"], "gold": ["light dizziness"], "text": "Precisely, only 3 participants complained of very light dizziness."}, {"generated": ["CL/F", "quinine", "T1/2"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["CL/F", "quinine", "T1/2"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["CL/F", "quinine", "T1/2"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["pharmacology"], "gold": [], "text": "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials."}, {"generated": ["MOS-HIV"], "gold": [], "text": "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group."}, {"generated": ["high density lipoprotein", "low density lipoprotein"], "gold": [], "text": "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time."}, {"generated": ["high density lipoprotein", "low density lipoprotein"], "gold": [], "text": "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(PDF) Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(PDF) Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(PDF) Click here for additional data file."}, {"generated": ["pathologies or side effects found in the text"], "gold": [], "text": "Thabethe, D.A."}, {"generated": ["prevalence", "occurrence", "side effects"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["prevalence", "occurrence", "side effects"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["prevalence", "occurrence", "side effects"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["interactions with other drugs"], "gold": [], "text": "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously."}, {"generated": ["prevalent among middle-aged (50\u201364) patients"], "gold": [], "text": "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups."}, {"generated": ["common cold", "respiratory problems"], "gold": [], "text": "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend."}, {"generated": ["common cold", "respiratory problems"], "gold": [], "text": "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend."}, {"generated": ["27"], "gold": [], "text": "[27] In the study performed by Roozbeh et al."}, {"generated": ["Karnofsky performance status scale", "neurological deficiencies"], "gold": ["neurological deficiencies"], "text": "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM)."}, {"generated": ["positron emission tomography positive residual tumor"], "gold": ["tumor"], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["interactions with herbal formulas"], "gold": [], "text": "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas."}, {"generated": ["clotting time"], "gold": [], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["S-warfarin"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["no specific pathologies or side effects mentioned"], "gold": [], "text": "However, this did not reach statistical significance (data not shown)."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["anticancer drugs", "adverse interactions"], "gold": ["cancer patients"], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["anticancer drugs", "adverse interactions"], "gold": ["cancer patients"], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["elderly"], "gold": [], "text": "It therefore was recommended that they should be avoided in the elderly [10, 12]."}, {"generated": ["completeness and validity of data", "clinical relevance of the results", "potential bias in the presentation of results and conclusions"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["completeness and validity of data", "clinical relevance of the results", "potential bias in the presentation of results and conclusions"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["completeness and validity of data", "clinical relevance of the results", "potential bias in the presentation of results and conclusions"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results."}, {"generated": ["drug-induced liver injury", "hepatotoxicity", "liver toxicity"], "gold": [], "text": "[36]."}, {"generated": ["drug-induced liver injury", "hepatotoxicity", "liver toxicity"], "gold": [], "text": "[36]."}, {"generated": ["drug-induced liver injury", "hepatotoxicity", "liver toxicity"], "gold": [], "text": "[36]."}, {"generated": ["Not specified in the provided text"], "gold": [], "text": "The results were not presented in detail but indicated that the two drugs act independently from each other."}, {"generated": ["pharmacodynamic interaction", "drugs"], "gold": [], "text": "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports."}, {"generated": ["pharmacodynamic interaction", "drugs"], "gold": [], "text": "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports."}, {"generated": ["opioids", "delirium"], "gold": ["delirium"], "text": "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible."}, {"generated": ["pharmacodynamic interactions"], "gold": [], "text": "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations."}, {"generated": ["no specific pathologies or side effects mentioned in the provided text"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["CYP3A inhibition", "CYP3A induction"], "gold": [], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["CYP3A inhibition", "CYP3A induction"], "gold": [], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["antidepressant"], "gold": [], "text": "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant."}, {"generated": ["radiological abnormalities", "left ventricular ejection fraction (LVEF)"], "gold": ["the radiological abnormalities"], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["radiological abnormalities", "left ventricular ejection fraction (LVEF)"], "gold": ["the radiological abnormalities"], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["doen\u00e7as autoimunes"], "gold": [], "text": "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica."}, {"generated": ["acumula\u00e7\u00e3o t\u00f3xica", "manifesta\u00e7\u00e3o cl\u00ednica"], "gold": [], "text": "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente."}, {"generated": ["acumula\u00e7\u00e3o t\u00f3xica", "manifesta\u00e7\u00e3o cl\u00ednica"], "gold": [], "text": "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente."}, {"generated": ["sedimento urin\u00e1rio", "par\u00e2metros hep\u00e1ticos", "par\u00e2metros renais", "prote\u00ednas do complemento"], "gold": [], "text": "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais."}, {"generated": ["sedimento urin\u00e1rio", "par\u00e2metros hep\u00e1ticos", "par\u00e2metros renais", "prote\u00ednas do complemento"], "gold": [], "text": "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais."}, {"generated": ["sedimento urin\u00e1rio", "par\u00e2metros hep\u00e1ticos", "par\u00e2metros renais", "prote\u00ednas do complemento"], "gold": [], "text": "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais."}, {"generated": ["sedimento urin\u00e1rio", "par\u00e2metros hep\u00e1ticos", "par\u00e2metros renais", "prote\u00ednas do complemento"], "gold": [], "text": "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais."}, {"generated": ["major side effects"], "gold": [], "text": "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada."}, {"generated": ["previamente h\u00edgida"], "gold": [], "text": "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas."}, {"generated": ["adverse reactions", "degree and result of the adverse reaction"], "gold": ["adverse reactions", "adverse reaction"], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["severe adverse reactions"], "gold": ["adverse reactions"], "text": "It is noteworthy that no severe adverse reactions were observed in this study."}, {"generated": ["large-scale menopausal subjects"], "gold": ["menopausal"], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": ["competitive inhibition"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["120-fold variability", "13-fold variability", "serotonin glucuronidation"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["120-fold variability", "13-fold variability", "serotonin glucuronidation"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["120-fold variability", "13-fold variability", "serotonin glucuronidation"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["metabolism of drugs", "valproic acid", "clofibric acid"], "gold": [], "text": "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25]."}, {"generated": ["metabolism of drugs", "valproic acid", "clofibric acid"], "gold": [], "text": "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25]."}, {"generated": ["metabolism of drugs", "valproic acid", "clofibric acid"], "gold": [], "text": "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25]."}, {"generated": ["previous study"], "gold": [], "text": "The previous study performed by Du et al."}, {"generated": ["potential for interactions with other drugs"], "gold": [], "text": "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14]."}, {"generated": ["deviation of \u00b11 day"], "gold": [], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["PCOS (Polycystic Ovary Syndrome)"], "gold": ["PCOS", "side effects"], "text": "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13]."}, {"generated": ["decreases blood glucose", "decreases insulin"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["decreases blood glucose", "decreases insulin"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["described pathologies or side effects"], "gold": [], "text": "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable."}, {"generated": ["HOMA-IR level", "insulin level", "no significant difference in the FBS level"], "gold": [], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": ["HOMA-IR level", "insulin level", "no significant difference in the FBS level"], "gold": [], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": ["HOMA-IR level", "insulin level", "no significant difference in the FBS level"], "gold": [], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": ["increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased"], "gold": [], "text": "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17]."}, {"generated": ["hypoglycemic"], "gold": [], "text": "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57]."}, {"generated": ["reduction of insulin tolerance", "hypolipidemic effects", "glucose levels"], "gold": [], "text": "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61]."}, {"generated": ["reduction of insulin tolerance", "hypolipidemic effects", "glucose levels"], "gold": [], "text": "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61]."}, {"generated": ["reduction of insulin tolerance", "hypolipidemic effects", "glucose levels"], "gold": [], "text": "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61]."}, {"generated": ["study"], "gold": [], "text": "All of this research is consistent with our study."}, {"generated": ["HIV strains"], "gold": ["AIDS", "HIV"], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["V05895B"], "gold": [], "text": "V05895B; Arkopharma, Madrid, Spain)."}, {"generated": ["clinical interview", "physical examination", "HIV-1 RNA load", "CD4+ T-cell count"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["clinical interview", "physical examination", "HIV-1 RNA load", "CD4+ T-cell count"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["clinical interview", "physical examination", "HIV-1 RNA load", "CD4+ T-cell count"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["clinical interview", "physical examination", "HIV-1 RNA load", "CD4+ T-cell count"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["CD4+ T-cell count"], "gold": [], "text": "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3."}, {"generated": ["HIV-1 RNA load"], "gold": ["adverse events", "patient"], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": ["Darunavir"], "gold": [], "text": "Darunavir pharmacokinetics."}, {"generated": ["no evident safety issue of concern"], "gold": [], "text": "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern."}, {"generated": ["DEX", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["DEX", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["DEX", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["DEX", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["CYPs"], "gold": [], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["CYP2C9", "CYP1A2"], "gold": [], "text": "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28]."}, {"generated": ["CYP2C9", "CYP1A2"], "gold": [], "text": "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28]."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Type of participant."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Type of participant."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Type of participant."}, {"generated": ["standard eligibility inclusion criteria", "two reviewers"], "gold": [], "text": "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers."}, {"generated": ["standard eligibility inclusion criteria", "two reviewers"], "gold": [], "text": "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers."}, {"generated": ["herbal preparations", "side effects", "bioanalytical data", "pathological conditions"], "gold": [], "text": "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2."}, {"generated": ["herbal preparations", "side effects", "bioanalytical data", "pathological conditions"], "gold": [], "text": "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2."}, {"generated": ["herbal preparations", "side effects", "bioanalytical data", "pathological conditions"], "gold": [], "text": "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2."}, {"generated": ["herbal preparations", "side effects", "bioanalytical data", "pathological conditions"], "gold": [], "text": "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2."}, {"generated": ["attrition", "withdrawal"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["attrition", "withdrawal"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["unclear risk of bias", "high risk of bias"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["unclear risk of bias", "high risk of bias"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["PD interactions", "herbal medicines"], "gold": [], "text": "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study."}, {"generated": ["PD interactions", "herbal medicines"], "gold": [], "text": "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study."}, {"generated": ["herb-warfarin interaction"], "gold": [], "text": "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship."}, {"generated": ["case reports", "misleading conclusions"], "gold": [], "text": "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40]."}, {"generated": ["case reports", "misleading conclusions"], "gold": [], "text": "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40]."}, {"generated": ["hepatic damage"], "gold": [], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["no pathologies or side effects mentioned"], "gold": [], "text": "However, no studies were reported these data."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(DOCX) Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(DOCX) Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(DOCX) Click here for additional data file."}, {"generated": ["international normalized ratio (INR)", "prothrombin time (PT)", "activated partial thromboplastin time (aPTT)"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["international normalized ratio (INR)", "prothrombin time (PT)", "activated partial thromboplastin time (aPTT)"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["international normalized ratio (INR)", "prothrombin time (PT)", "activated partial thromboplastin time (aPTT)"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["disseminated intravascular coagulation (DIC)", "pathologic inhibitors of coagulation", "coagulopathy of unknown origin", "vitamin K malabsorption"], "gold": ["coagulopathy", "pathologic inhibitors of coagulation", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption"], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": ["herb\u2013drug interactions", "ADME processes"], "gold": [], "text": "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms."}, {"generated": ["herb\u2013drug interactions", "ADME processes"], "gold": [], "text": "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Supporting Information Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Supporting Information Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Supporting Information Click here for additional data file."}, {"generated": ["curcumin"], "gold": [], "text": "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier."}, {"generated": ["CBZ", "hurdles", "comprehensive systematic review"], "gold": [], "text": "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions."}, {"generated": ["CBZ", "hurdles", "comprehensive systematic review"], "gold": [], "text": "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions."}, {"generated": ["CBZ", "hurdles", "comprehensive systematic review"], "gold": [], "text": "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions."}, {"generated": ["no specific pathologies or side effects mentioned directly in the text provided"], "gold": [], "text": "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec."}, {"generated": ["2012"], "gold": [], "text": "2012)."}, {"generated": ["antiepileptic therapy"], "gold": ["Patients"], "text": "Patients on antiepileptic therapy are usually on a long-term basis."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "In order to achieve a comprehensive literature search, a total of eleven databases were searched."}, {"generated": ["other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, SciFinder Scholar)", "Chinese databases", "conventional databases (EMBASE, MEDLINE)"], "gold": [], "text": "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases."}, {"generated": ["other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, SciFinder Scholar)", "Chinese databases", "conventional databases (EMBASE, MEDLINE)"], "gold": [], "text": "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases."}, {"generated": ["other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, SciFinder Scholar)", "Chinese databases", "conventional databases (EMBASE, MEDLINE)"], "gold": [], "text": "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases."}, {"generated": ["cycloserine (CBZ)"], "gold": [], "text": "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption."}, {"generated": ["side effects", "caution"], "gold": [], "text": "Caution should also be paid for beverage containing alcohol."}, {"generated": ["side effects", "caution"], "gold": [], "text": "Caution should also be paid for beverage containing alcohol."}, {"generated": ["variables", "side effects", "significant relationship"], "gold": [], "text": "A significant relationship between variables was identified if p < 0.05."}, {"generated": ["variables", "side effects", "significant relationship"], "gold": [], "text": "A significant relationship between variables was identified if p < 0.05."}, {"generated": ["variables", "side effects", "significant relationship"], "gold": [], "text": "A significant relationship between variables was identified if p < 0.05."}, {"generated": ["summary characteristics of interviewed patients"], "gold": [], "text": "A summary of the background characteristics of the interviewed patients is given in Table 1."}, {"generated": ["hypoglycaemic agents"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["hepatocellular carcinoma"], "gold": ["carcinoma"], "text": "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7]."}, {"generated": ["22 compounds identified or tentatively identified"], "gold": [], "text": "A total of 22 compounds were identified or tentatively identified (Figure 1)."}, {"generated": ["liver drug enzymes"], "gold": [], "text": "Liver drug enzymes are the common sites of drug interaction in human."}, {"generated": ["PON"], "gold": [], "text": "The influence test for PON was conducted by the method of Furlong et al."}, {"generated": ["significant differences", "side effects", "control group"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["significant differences", "side effects", "control group"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["significant differences", "side effects", "control group"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["pharmacological safety", "herbal medicines"], "gold": [], "text": "However, there is hardly any data on the pharmacological safety of these two herbal medicines."}, {"generated": ["pharmacological safety", "herbal medicines"], "gold": [], "text": "However, there is hardly any data on the pharmacological safety of these two herbal medicines."}, {"generated": ["L-MDR1 cells", "human P-glycoprotein (P-gp)"], "gold": [], "text": "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown)."}, {"generated": ["L-MDR1 cells", "human P-glycoprotein (P-gp)"], "gold": [], "text": "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown)."}, {"generated": ["CYP3A4", "CYP2C19"], "gold": [], "text": "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%)."}, {"generated": ["CYP3A4", "CYP2C19"], "gold": [], "text": "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%)."}, {"generated": ["aryl hydrocarbon receptor (AhR)"], "gold": [], "text": "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B)."}, {"generated": ["BCRP"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["cyclosporine A", "positive controls rifampicin"], "gold": [], "text": "Results for the positive controls rifampicin and cyclosporine A were published previously [25]."}, {"generated": ["cyclosporine A", "positive controls rifampicin"], "gold": [], "text": "Results for the positive controls rifampicin and cyclosporine A were published previously [25]."}, {"generated": ["induction assay"], "gold": [], "text": "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay."}, {"generated": ["evaluated", "pathologies or side effects"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["evaluated", "pathologies or side effects"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["p < 0.01", "p < 0.05"], "gold": [], "text": "* p < 0.05, ** p < 0.01."}, {"generated": ["p < 0.01", "p < 0.05"], "gold": [], "text": "* p < 0.05, ** p < 0.01."}, {"generated": ["reporter gene assays"], "gold": [], "text": "Results of the reporter gene assays."}, {"generated": ["drug interactions"], "gold": [], "text": "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion."}, {"generated": ["no specific pathologies or side effects mentioned"], "gold": [], "text": "Its original formulation was in a tablet form."}, {"generated": ["side effects", "medications"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["side effects", "medications"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["CYP2B6 genotyping"], "gold": [], "text": "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13]."}, {"generated": ["side effects", "processed", "analytical data"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["side effects", "processed", "analytical data"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["side effects", "processed", "analytical data"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["no pathologies or side effects mentioned"], "gold": [], "text": "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data."}, {"generated": ["various malignancies"], "gold": [], "text": "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3]."}, {"generated": ["BCPR/ABCG2 protein"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["radical alteration"], "gold": [], "text": "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O."}, {"generated": ["7th day", "2 hours after APG 40 mg/kg administration"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["7th day", "2 hours after APG 40 mg/kg administration"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["in vivo studies", "side effects", "APG\u2013DAS interaction"], "gold": [], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": ["in vivo studies", "side effects", "APG\u2013DAS interaction"], "gold": [], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": ["in vivo studies", "side effects", "APG\u2013DAS interaction"], "gold": [], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": ["pathologies or side effects found in the text"], "gold": [], "text": "and M.A.A."}, {"generated": ["K.M.A.", "supervision"], "gold": [], "text": "; supervision, K.M.A."}, {"generated": ["K.M.A.", "supervision"], "gold": [], "text": "; supervision, K.M.A."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "All authors have read and agreed to the published version of the manuscript."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["toxicities", "side effects", "drug-resistant conditions", "pathologies", "drug-related diseases", "drug reactions", "drug-induced conditions", "pharmacology", "adverse effects", "drug-sensitive conditions"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["intestinal", "Hepatic"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["intestinal", "Hepatic"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["herb-mediated changes in CYP activity"], "gold": [], "text": "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population."}, {"generated": ["Resting lactate level"], "gold": [], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": ["high lactate production", "reduced oxidative metabolism"], "gold": [], "text": "have shown the association between high lactate production and reduced oxidative metabolism [47]."}, {"generated": ["high lactate production", "reduced oxidative metabolism"], "gold": [], "text": "have shown the association between high lactate production and reduced oxidative metabolism [47]."}, {"generated": ["pregnane\u2010X\u2010receptor (PXR) activation"], "gold": [], "text": "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["cancer therapies"], "gold": ["cancer"], "text": "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies."}, {"generated": ["clinical outcomes", "beneficial interactions", "harmful interactions", "mechanistic explanations"], "gold": ["cancer"], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["clinical outcomes", "beneficial interactions", "harmful interactions", "mechanistic explanations"], "gold": ["cancer"], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["clinical outcomes", "beneficial interactions", "harmful interactions", "mechanistic explanations"], "gold": ["cancer"], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["clinical outcomes", "beneficial interactions", "harmful interactions", "mechanistic explanations"], "gold": ["cancer"], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["process of database searching", "literature selection"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["process of database searching", "literature selection"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["tumor recurrence", "metastasis"], "gold": ["metastasis", "tumor"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["gut dysbiosis", "tumor metabolism"], "gold": ["gut dysbiosis"], "text": "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "a."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "a."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "a."}, {"generated": ["T cell balance", "immune responses", "T cell apoptosis", "T helper cell balance"], "gold": [], "text": "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171]."}, {"generated": ["T cell balance", "immune responses", "T cell apoptosis", "T helper cell balance"], "gold": [], "text": "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171]."}, {"generated": ["T cell balance", "immune responses", "T cell apoptosis", "T helper cell balance"], "gold": [], "text": "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171]."}, {"generated": ["T cell balance", "immune responses", "T cell apoptosis", "T helper cell balance"], "gold": [], "text": "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171]."}, {"generated": ["adverse effects of chemotherapeutic drugs"], "gold": ["adverse effects"], "text": "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings."}, {"generated": ["pathologies or side effects found in the text"], "gold": [], "text": "Table S4."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["medication-induced conditions", "pharmacodynamics", "drug-related side effects", "adverse drug reactions", "drug-drug interactions", "drug-induced organ failure", "drug-induced organ damage", "drug-induced organ dysfunction", "therapeutic drug monitoring", "drug-induced organ toxicity", "drug resistance", "drug hypersensitivity", "pharmacology", "pharmacokinetics", "drug tolerance", "drug interactions"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Not applicable."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Not applicable."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Not applicable."}, {"generated": ["estrogen receptor (ER) positive", "breast tumors"], "gold": ["breast tumors", "ER-positive breast cancer"], "text": "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer."}, {"generated": ["other types of cancer", "breast cancer"], "gold": ["cancer", "breast cancer"], "text": "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313]."}, {"generated": ["total mistletoe lectin concentration"], "gold": [], "text": "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec."}, {"generated": ["proliferation"], "gold": [], "text": "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig."}, {"generated": ["patients"], "gold": [], "text": "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33]."}, {"generated": ["inter-individual variability", "genetic polymorphisms"], "gold": [], "text": "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41]."}, {"generated": ["inter-individual variability", "genetic polymorphisms"], "gold": [], "text": "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41]."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(PDF 36 kb) Figure S2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(PDF 36 kb) Figure S2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(PDF 36 kb) Figure S2."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["daily for two weeks at morning"], "gold": [], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["within-run accuracy", "captopril analysis", "within-run precision"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["within-run accuracy", "captopril analysis", "within-run precision"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["within-run accuracy", "captopril analysis", "within-run precision"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["selectivity testing"], "gold": [], "text": "In selectivity testing, six rats plasma was used."}, {"generated": ["reaction"], "gold": [], "text": "The reaction was then stopped by adding formic acid [17]."}, {"generated": ["2016; Eng et al."], "gold": [], "text": "2016; Eng et\u00a0al."}, {"generated": ["drug-induced liver injury", "hepatotoxicity"], "gold": [], "text": "2016)."}, {"generated": ["drug-induced liver injury", "hepatotoxicity"], "gold": [], "text": "2016)."}, {"generated": ["translational science", "pharmacology"], "gold": [], "text": "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?"}, {"generated": ["translational science", "pharmacology"], "gold": [], "text": "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?"}, {"generated": ["drug-induced liver injury", "liver enzyme elevation", "liver damage", "liver toxicity", "liver dysfunction", "hepatotoxicity"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["drug-induced liver injury", "liver enzyme elevation", "liver damage", "liver toxicity", "liver dysfunction", "hepatotoxicity"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["drug-induced liver injury", "liver enzyme elevation", "liver damage", "liver toxicity", "liver dysfunction", "hepatotoxicity"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["drug-induced liver injury", "liver enzyme elevation", "liver damage", "liver toxicity", "liver dysfunction", "hepatotoxicity"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["drug-induced liver injury", "liver enzyme elevation", "liver damage", "liver toxicity", "liver dysfunction", "hepatotoxicity"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["drug-induced liver injury", "liver enzyme elevation", "liver damage", "liver toxicity", "liver dysfunction", "hepatotoxicity"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "wrote the manuscript."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["E.H. syndrome", "H.O. syndrome", "K.S. syndrome", "Y.O. syndrome", "T.O. syndrome", "S.M. syndrome", "R.T. syndrome"], "gold": [], "text": "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["Y.O.", "S.M.", "H.W.", "J.K.", "M.F.", "K.S.", "R.T."], "gold": [], "text": "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S."}, {"generated": ["seven days"], "gold": [], "text": "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing."}, {"generated": ["filtered", "previous filtrate"], "gold": [], "text": "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate."}, {"generated": ["filtered", "previous filtrate"], "gold": [], "text": "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate."}, {"generated": ["toxicities", "drug-induced diseases", "side effects", "pathology", "pharmacology", "adverse effects"], "gold": [], "text": "3a and b)."}, {"generated": ["toxicities", "drug-induced diseases", "side effects", "pathology", "pharmacology", "adverse effects"], "gold": [], "text": "3a and b)."}, {"generated": ["toxicities", "drug-induced diseases", "side effects", "pathology", "pharmacology", "adverse effects"], "gold": [], "text": "3a and b)."}, {"generated": ["toxicities", "drug-induced diseases", "side effects", "pathology", "pharmacology", "adverse effects"], "gold": [], "text": "3a and b)."}, {"generated": ["toxicities", "drug-induced diseases", "side effects", "pathology", "pharmacology", "adverse effects"], "gold": [], "text": "3a and b)."}, {"generated": ["toxicities", "drug-induced diseases", "side effects", "pathology", "pharmacology", "adverse effects"], "gold": [], "text": "3a and b)."}, {"generated": ["inflammatory response", "oxidative stress", "liver damage", "diabetes"], "gold": ["aberrant inflammatory response", "oxidative stress", "liver damage", "diabetes"], "text": "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response."}, {"generated": ["mean \u00b1 standard error of measurement (SEM)"], "gold": [], "text": "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats."}, {"generated": ["significantly different from normal group", "significantly different from diabetic control group"], "gold": ["diabetic"], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different from normal group", "significantly different from diabetic control group"], "gold": ["diabetic"], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["elevated levels of BUN"], "gold": [], "text": "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig."}, {"generated": ["drug-induced liver injury", "hepatotoxicity"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["drug-induced liver injury", "hepatotoxicity"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["significantly different from normal group", "significantly different from diabetic control group"], "gold": ["diabetic"], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different from normal group", "significantly different from diabetic control group"], "gold": ["diabetic"], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["model group", "M-AOE group"], "gold": [], "text": "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group."}, {"generated": ["model group", "M-AOE group"], "gold": [], "text": "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group."}, {"generated": ["indomethacin-induced gastric injury"], "gold": ["gastric injury"], "text": "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "1)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "1)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "1)."}, {"generated": ["anticoagulant therapy"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.)."}, {"generated": ["warfarin"], "gold": [], "text": "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement."}, {"generated": ["prosthetic heart valves", "warfarin"], "gold": ["prosthetic heart"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["prosthetic heart valves", "warfarin"], "gold": ["prosthetic heart"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["no specific pathologies or side effects mentioned"], "gold": [], "text": "Go to: Conflict of interests  There is no conflict of interests."}, {"generated": ["reduces blood pressure"], "gold": [], "text": "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "7.2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "7.2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "7.2."}, {"generated": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "LDL-C"], "gold": [], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "LDL-C"], "gold": [], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "LDL-C"], "gold": [], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "LDL-C"], "gold": [], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "LDL-C"], "gold": [], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["significant increase in total cholesterol"], "gold": ["hypertensive"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": ["electrolyte levels", "diuretic effects"], "gold": ["diuretic effects"], "text": "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "As a service to our customers we are providing this early version of the manuscript."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "As a service to our customers we are providing this early version of the manuscript."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "As a service to our customers we are providing this early version of the manuscript."}, {"generated": ["herb-drug interactions"], "gold": [], "text": "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Go to: 2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Go to: 2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Go to: 2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "2.1.2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "2.1.2."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "2.1.2."}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["mechanism\u2010based inhibition"], "gold": [], "text": "MBI, mechanism\u2010based inhibition Go to: 4."}, {"generated": ["chronic exposure"], "gold": [], "text": "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction."}, {"generated": ["cancer cell lines"], "gold": ["anti\u2010cancer activity"], "text": "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines."}, {"generated": ["warfarin", "Gegen", "Danshen"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["warfarin", "Gegen", "Danshen"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["warfarin", "Gegen", "Danshen"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["no specific pathologies or side effects mentioned directly in the text provided"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["inhibiting platelet aggregation", "inhibiting the activity of VKOR", "inducing TM", "anticoagulant effect", "improving microcirculation"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["inhibiting platelet aggregation", "inhibiting the activity of VKOR", "inducing TM", "anticoagulant effect", "improving microcirculation"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["inhibiting platelet aggregation", "inhibiting the activity of VKOR", "inducing TM", "anticoagulant effect", "improving microcirculation"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["inhibiting platelet aggregation", "inhibiting the activity of VKOR", "inducing TM", "anticoagulant effect", "improving microcirculation"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["inhibiting platelet aggregation", "inhibiting the activity of VKOR", "inducing TM", "anticoagulant effect", "improving microcirculation"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["Gegen"], "gold": [], "text": "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG."}, {"generated": ["interactions between Gegen and warfarin", "case reports", "interact with warfarin"], "gold": [], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": ["interactions between Gegen and warfarin", "case reports", "interact with warfarin"], "gold": [], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": ["interactions between Gegen and warfarin", "case reports", "interact with warfarin"], "gold": [], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": ["warfarin dose"], "gold": [], "text": "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54]."}, {"generated": ["warfarin hydroxylation"], "gold": [], "text": "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58]."}, {"generated": ["liver cytochrome P450"], "gold": [], "text": "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study."}, {"generated": ["publication by (Beer et al.)"], "gold": [], "text": "Sample preparation was based on the publication by (Beer et al."}, {"generated": ["adjuvant chemotherapy"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["competing interests"], "gold": [], "text": "Competing interests          The authors have declared no conflicts of interests."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "hypertension", "malaria", "antimicrobials", "asthma"], "gold": ["cancer", "peptic ulcer", "diabetes", "hypertension", "asthma"], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "hypertension", "malaria", "antimicrobials", "asthma"], "gold": ["cancer", "peptic ulcer", "diabetes", "hypertension", "asthma"], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["no specific pathologies or side effects mentioned in the provided text"], "gold": [], "text": "Strandell et\u00a0al."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(2000)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(2000)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "(2000)."}, {"generated": ["sexual dysfunction", "cognitive declines", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": ["sexual dysfunction", "cognitive declines", "mood disorders", "weight gain", "night sweats", "menopause", "hot flashes", "sleep disturbances"], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["no specific pathologies or side effects mentioned in the provided text"], "gold": [], "text": "34860-2.5L-R) and ammonium acetate (catalog No."}, {"generated": ["half-maximal inhibitory concentration (IC50)", "ethics committees", "side effects", "approval No."], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["half-maximal inhibitory concentration (IC50)", "ethics committees", "side effects", "approval No."], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["half-maximal inhibitory concentration (IC50)", "ethics committees", "side effects", "approval No."], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["half-maximal inhibitory concentration (IC50)", "ethics committees", "side effects", "approval No."], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["planning to conceive", "breastfeeding", "pregnancy"], "gold": [], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": ["planning to conceive", "breastfeeding", "pregnancy"], "gold": [], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": ["planning to conceive", "breastfeeding", "pregnancy"], "gold": [], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": ["MenoAct851 formulation"], "gold": [], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": ["pharmacology"], "gold": [], "text": "Values are expressed as mean (SD)."}, {"generated": ["significant", "differences", "P < 0.05"], "gold": [], "text": "A difference was considered significant at P < 0.05."}, {"generated": ["significant", "differences", "P < 0.05"], "gold": [], "text": "A difference was considered significant at P < 0.05."}, {"generated": ["significant", "differences", "P < 0.05"], "gold": [], "text": "A difference was considered significant at P < 0.05."}, {"generated": ["simvastatin"], "gold": [], "text": "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin."}, {"generated": ["drug interactions"], "gold": ["illnesses"], "text": "Drug interactions can be considered illnesses by themselves."}, {"generated": ["lifestyle interactions", "interactions between medication and lifestyle", "medication interactions", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["lifestyle interactions", "interactions between medication and lifestyle", "medication interactions", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["lifestyle interactions", "interactions between medication and lifestyle", "medication interactions", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["lifestyle interactions", "interactions between medication and lifestyle", "medication interactions", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["CYP2C9*2", "CYP2C9*1", "CYP2C9*3"], "gold": [], "text": "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis."}, {"generated": ["CYP2C9*2", "CYP2C9*1", "CYP2C9*3"], "gold": [], "text": "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis."}, {"generated": ["CYP2C9*2", "CYP2C9*1", "CYP2C9*3"], "gold": [], "text": "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis."}, {"generated": ["warfarin", "adverse events", "herbal medicines"], "gold": ["adverse events"], "text": "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported."}, {"generated": ["warfarin", "adverse events", "herbal medicines"], "gold": ["adverse events"], "text": "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported."}, {"generated": ["Arachidonic acid", "Collagen", "ADP"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["Arachidonic acid", "Collagen", "ADP"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["Arachidonic acid", "Collagen", "ADP"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["No specific pathologies or side effects mentioned in the provided text snippet"], "gold": [], "text": "Gorski et al."}, {"generated": ["discrepancy", "previous studies"], "gold": [], "text": "The reason for the discrepancy with previous studies remains unclear."}, {"generated": ["discrepancy", "previous studies"], "gold": [], "text": "The reason for the discrepancy with previous studies remains unclear."}, {"generated": ["Panax ginseng", "Ginkgo biloba", "Hypericum perforatum", "Clinical studies", "plants", "Allium sativum"], "gold": [], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": ["Panax ginseng", "Ginkgo biloba", "Hypericum perforatum", "Clinical studies", "plants", "Allium sativum"], "gold": [], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": ["Panax ginseng", "Ginkgo biloba", "Hypericum perforatum", "Clinical studies", "plants", "Allium sativum"], "gold": [], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": ["Panax ginseng", "Ginkgo biloba", "Hypericum perforatum", "Clinical studies", "plants", "Allium sativum"], "gold": [], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": ["Panax ginseng", "Ginkgo biloba", "Hypericum perforatum", "Clinical studies", "plants", "Allium sativum"], "gold": [], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": ["Panax ginseng", "Ginkgo biloba", "Hypericum perforatum", "Clinical studies", "plants", "Allium sativum"], "gold": [], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": ["drug-induced liver injury", "hepatotoxicity", "liver toxicity"], "gold": [], "text": "[35]."}, {"generated": ["drug-induced liver injury", "hepatotoxicity", "liver toxicity"], "gold": [], "text": "[35]."}, {"generated": ["drug-induced liver injury", "hepatotoxicity", "liver toxicity"], "gold": [], "text": "[35]."}, {"generated": ["Disease", "side effects", "worse than the disease"], "gold": ["the Disease"], "text": "Worse than the Disease?"}, {"generated": ["Disease", "side effects", "worse than the disease"], "gold": ["the Disease"], "text": "Worse than the Disease?"}, {"generated": ["Disease", "side effects", "worse than the disease"], "gold": ["the Disease"], "text": "Worse than the Disease?"}, {"generated": ["rashes caused by Lomatium"], "gold": ["rashes", "the rash"], "text": "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion."}, {"generated": ["pruritis", "rash"], "gold": ["the rash", "pruritis"], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["Day 5"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["OSA (Obesity Sleep Apnea)"], "gold": [], "text": "The formation rate of OSA could be significantly suppressed by all the herb/herbal components."}, {"generated": ["RLM", "hCE1"], "gold": [], "text": "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs."}, {"generated": ["RLM", "hCE1"], "gold": [], "text": "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs."}, {"generated": ["OS", "OSA"], "gold": [], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": ["OS", "OSA"], "gold": [], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": ["OSA (Obstructive Sleep Apnoea)"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "S8)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "S8)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "S8)."}, {"generated": ["herb/herbal component effect on OS"], "gold": [], "text": "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS."}, {"generated": ["Root of Isatis indigotica Fort., Banlangen"], "gold": [], "text": "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen)."}, {"generated": ["Niubangzi"], "gold": [], "text": "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi)."}, {"generated": ["clinical breast cancer"], "gold": ["breast cancer"], "text": "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions."}, {"generated": ["Ginger (Zingiber officinale Roscoe) - may cause heartburn, diarrhea, and bleeding", "Licorice (Glycyrrhiza glabra L.) - may cause hypokalemia, congestive heart failure, and edema", "Lilyturf (Ophiopogon japonicus (Thunb.)) - may cause liver toxicity"], "gold": [], "text": "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)"}, {"generated": ["Ginger (Zingiber officinale Roscoe) - may cause heartburn, diarrhea, and bleeding", "Licorice (Glycyrrhiza glabra L.) - may cause hypokalemia, congestive heart failure, and edema", "Lilyturf (Ophiopogon japonicus (Thunb.)) - may cause liver toxicity"], "gold": [], "text": "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)"}, {"generated": ["Ginger (Zingiber officinale Roscoe) - may cause heartburn, diarrhea, and bleeding", "Licorice (Glycyrrhiza glabra L.) - may cause hypokalemia, congestive heart failure, and edema", "Lilyturf (Ophiopogon japonicus (Thunb.)) - may cause liver toxicity"], "gold": [], "text": "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)"}, {"generated": ["autophagy", "cell cycle arrest", "apoptosis"], "gold": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"], "text": "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013)."}, {"generated": ["autophagy", "cell cycle arrest", "apoptosis"], "gold": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"], "text": "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013)."}, {"generated": ["autophagy", "cell cycle arrest", "apoptosis"], "gold": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"], "text": "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013)."}, {"generated": ["T-47D", "MCF-7"], "gold": [], "text": "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010)."}, {"generated": ["T-47D", "MCF-7"], "gold": [], "text": "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010)."}, {"generated": ["TAM-resistant MCF-7/TAM-R cells"], "gold": [], "text": "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)."}, {"generated": ["TAM-intoxicated liver injury"], "gold": ["liver injury", "the oxidative stress"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["BCRP", "OAT1/3", "MDR1"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["BCRP", "OAT1/3", "MDR1"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["BCRP", "OAT1/3", "MDR1"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["CIP"], "gold": [], "text": "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990)."}, {"generated": ["biliary excretion", "secretion into breast milk", "intestinal secretion"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["biliary excretion", "secretion into breast milk", "intestinal secretion"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["biliary excretion", "secretion into breast milk", "intestinal secretion"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Click here for additional data file."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Click here for additional data file."}, {"generated": ["24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["concomitant herbal use"], "gold": [], "text": "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6]."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["echinacea", "kratom", "St. John\u2019s wort", "hydroxycut", "piperine", "celery", "rhodiola", "gingko", "moringa", "terminalia/commiphora ayurvedic mixture", "valerian", "ginseng", "kava"], "gold": [], "text": "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian."}, {"generated": ["severity", "consequences", "anecdotal evidence"], "gold": [], "text": "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions."}, {"generated": ["severity", "consequences", "anecdotal evidence"], "gold": [], "text": "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions."}, {"generated": ["severity", "consequences", "anecdotal evidence"], "gold": [], "text": "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions."}, {"generated": ["general concern about its safety"], "gold": [], "text": "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits."}, {"generated": ["clinically relevant interaction"], "gold": [], "text": "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104]."}, {"generated": ["serotonergic effects", "interactions"], "gold": [], "text": "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects."}, {"generated": ["serotonergic effects", "interactions"], "gold": [], "text": "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects."}, {"generated": ["side effects", "herbal products"], "gold": [], "text": "This is important because the vast majority of herbal products are orally administered."}, {"generated": ["side effects", "herbal products"], "gold": [], "text": "This is important because the vast majority of herbal products are orally administered."}, {"generated": ["mixtures of different herbal species", "dietary supplements", "marketed herbal products"], "gold": [], "text": "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood."}, {"generated": ["mixtures of different herbal species", "dietary supplements", "marketed herbal products"], "gold": [], "text": "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood."}, {"generated": ["mixtures of different herbal species", "dietary supplements", "marketed herbal products"], "gold": [], "text": "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood."}, {"generated": ["interactions with specific neuropsychiatric drugs"], "gold": [], "text": "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs."}, {"generated": ["immunosuppressive agents"], "gold": [], "text": "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation."}, {"generated": ["tremors", "tacrolimus-based immunosuppression"], "gold": ["tremors"], "text": "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors."}, {"generated": ["serum creatinine level"], "gold": [], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": ["pharmacology"], "gold": [], "text": "Author contributions: MK drafted the initial and final versions of the manuscript."}, {"generated": ["immunosuppressive drug", "graft rejection"], "gold": ["graft rejection"], "text": "Sirolimus is an immunosuppressive drug used to prevent graft rejection."}, {"generated": ["immunosuppressive drugs"], "gold": [], "text": "Therapeutic drug monitoring is required as with other immunosuppressive drugs."}, {"generated": ["serum creatinine level"], "gold": [], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": ["pharmacology"], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["Zuccor phenomenon", "QT interval prolongation", "cardiac arrhythmias"], "gold": [], "text": "et Zucc.)"}, {"generated": ["Zuccor phenomenon", "QT interval prolongation", "cardiac arrhythmias"], "gold": [], "text": "et Zucc.)"}, {"generated": ["Zuccor phenomenon", "QT interval prolongation", "cardiac arrhythmias"], "gold": [], "text": "et Zucc.)"}, {"generated": ["combined extraction solution"], "gold": [], "text": "The combined extraction solution was then evaporated to dryness."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["regulatory environment", "Europe", "Bilia and C\u00e9u Costas review"], "gold": [], "text": "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]."}, {"generated": ["regulatory environment", "Europe", "Bilia and C\u00e9u Costas review"], "gold": [], "text": "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]."}, {"generated": ["regulatory environment", "Europe", "Bilia and C\u00e9u Costas review"], "gold": [], "text": "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "It most often means that we have less knowledge of benefits, as well as risks."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "It most often means that we have less knowledge of benefits, as well as risks."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "It most often means that we have less knowledge of benefits, as well as risks."}, {"generated": ["analgetic drugs", "non-pharmacological treatments"], "gold": [], "text": "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years."}, {"generated": ["analgetic drugs", "non-pharmacological treatments"], "gold": [], "text": "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years."}, {"generated": ["list of pathologies", "frequently occurring species", "combined literature"], "gold": [], "text": "From the combined literature, a list of the most frequently occurring species was established."}, {"generated": ["list of pathologies", "frequently occurring species", "combined literature"], "gold": [], "text": "From the combined literature, a list of the most frequently occurring species was established."}, {"generated": ["list of pathologies", "frequently occurring species", "combined literature"], "gold": [], "text": "From the combined literature, a list of the most frequently occurring species was established."}, {"generated": ["prevalence"], "gold": [], "text": "They found a prevalence of 56.6%."}, {"generated": ["Aloe vera"], "gold": [], "text": "A Spanish study reports Aloe vera [37]."}, {"generated": ["short-term use of opioids"], "gold": ["pain"], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["insufficiently defined product quality"], "gold": [], "text": "There are only food supplements available, with insufficiently defined product quality."}, {"generated": ["possible beneficial effects"], "gold": [], "text": "This is debated, and there are hints to possible beneficial effects [135]."}, {"generated": ["dry extract", "ginkgolic acid content"], "gold": [], "text": "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154]."}, {"generated": ["dry extract", "ginkgolic acid content"], "gold": [], "text": "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154]."}, {"generated": ["thrombin inhibition"], "gold": [], "text": "There are in vitro experiments confirming thrombin inhibition [172]."}, {"generated": ["pathologies or side effects found in text"], "gold": [], "text": "Seong et al."}, {"generated": ["no specific pathologies or side effects mentioned in the provided text"], "gold": [], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}, {"generated": ["unusually susceptible", "individual genotype"], "gold": [], "text": "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207]."}, {"generated": ["unusually susceptible", "individual genotype"], "gold": [], "text": "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207]."}, {"generated": ["CYP2D9", "CYP3A4"], "gold": [], "text": "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230]."}, {"generated": ["CYP2D9", "CYP3A4"], "gold": [], "text": "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230]."}, {"generated": ["platelet aggregation"], "gold": [], "text": "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234]."}, {"generated": ["MTX doses", "ASA"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["MTX doses", "ASA"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["individual susceptibility"], "gold": [], "text": "The clinical significance of this phenomenon depends on individual susceptibility."}, {"generated": ["adverse effects", "side effects"], "gold": ["adverse effects"], "text": "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "This may result in translation errors or assigning mentions to the wrong species, in some cases."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "This may result in translation errors or assigning mentions to the wrong species, in some cases."}, {"generated": ["pathologies", "side effects", "pharmacology"], "gold": [], "text": "This may result in translation errors or assigning mentions to the wrong species, in some cases."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["diabetic treatment"], "gold": ["diabetic"], "text": "This herb has been in use for diabetic treatment for almost two millennia [72]."}, {"generated": ["conventional antidiabetics"], "gold": [], "text": "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86]."}, {"generated": ["98"], "gold": [], "text": "no interaction [98]."}, {"generated": ["pathologies or side effects"], "gold": [], "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["CYP2D6", "CYP3A"], "gold": [], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": ["CYP2D6", "CYP3A"], "gold": [], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": ["DOR (dihydrotestosterone)"], "gold": [], "text": "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig."}, {"generated": ["abemaciclib-related diarrhea"], "gold": ["diarrhea"], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}], "FN": [{"generated": ["rhabdomyolysis", "heavy toxicity", "retroperitoneal liposarcoma"], "gold": ["rhabdomyolysis", "adverse event", "retroperitoneal liposarcoma"], "text": "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event."}, {"generated": ["treatment-induced toxicity", "cancer-related syndromes"], "gold": ["treatment-induced toxicity", "cancer", "cancer-related syndromes"], "text": "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8]."}, {"generated": [], "gold": ["chronic back pain"], "text": "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes."}, {"generated": ["Parkinson's disease (PD)"], "gold": ["PD"], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": [], "gold": ["adverse drug events"], "text": "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events."}, {"generated": ["vitamin D deficiency", "chronic neck, back, and shoulder pain", "spinal stenosis"], "gold": ["spinal stenosis", "chronic neck, back, and shoulder pain", "mild kidney disease", "PD", "frequent falls", "vitamin D deficiency"], "text": "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain."}, {"generated": ["vitamin D deficiency", "chronic neck, back, and shoulder pain", "spinal stenosis"], "gold": ["spinal stenosis", "chronic neck, back, and shoulder pain", "mild kidney disease", "PD", "frequent falls", "vitamin D deficiency"], "text": "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain."}, {"generated": ["vitamin D deficiency", "chronic neck, back, and shoulder pain", "spinal stenosis"], "gold": ["spinal stenosis", "chronic neck, back, and shoulder pain", "mild kidney disease", "PD", "frequent falls", "vitamin D deficiency"], "text": "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain."}, {"generated": [], "gold": ["pain", "healthy"], "text": "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21]."}, {"generated": [], "gold": ["pain", "healthy"], "text": "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21]."}, {"generated": ["hallucinations"], "gold": ["PD", "hallucinations"], "text": "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12]."}, {"generated": [], "gold": ["pain"], "text": "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34]."}, {"generated": ["hypoglycemic effect"], "gold": ["hypoglycemic"], "text": "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043)."}, {"generated": ["traditional hypoglycemic herbs"], "gold": ["hypoglycemic"], "text": "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs."}, {"generated": ["diabetic patients"], "gold": ["diabetic"], "text": "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001)."}, {"generated": ["Epstein Barr virus (EBV)", "acute cytomegalovirus (CMV)"], "gold": ["Epstein Barr virus (EBV", "acute cytomegalovirus (CMV"], "text": "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative."}, {"generated": ["Epstein Barr virus (EBV)", "acute cytomegalovirus (CMV)"], "gold": ["Epstein Barr virus (EBV", "acute cytomegalovirus (CMV"], "text": "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative."}, {"generated": ["fibroinflammatory expansion of portal tracts", "plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "cholangiolar proliferation", "chronic hepatitis"], "gold": ["interface hepatitis", "chronic hepatitis"], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": [], "gold": ["menopause"], "text": "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15]."}, {"generated": ["black cohosh hepatotoxicity"], "gold": ["hepatotoxicity"], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": [], "gold": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"], "text": "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013)."}, {"generated": [], "gold": ["obesity", "diabetes"], "text": "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17]."}, {"generated": [], "gold": ["obesity", "diabetes"], "text": "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17]."}, {"generated": ["grade 3 and 4 toxicities"], "gold": ["toxicities", "Adverse Events", "Cancer"], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["grade 3 and 4 toxicities"], "gold": ["toxicities", "Adverse Events", "Cancer"], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["grade 3 and 4 toxicities"], "gold": ["toxicities", "Adverse Events", "Cancer"], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["advanced cancer"], "gold": ["tumour", "advanced cancer"], "text": "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer."}, {"generated": ["elevated or false-positive digoxin plasma concentration monitoring results"], "gold": ["renal dysfunction", "patients"], "text": "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results."}, {"generated": ["elevated or false-positive digoxin plasma concentration monitoring results"], "gold": ["renal dysfunction", "patients"], "text": "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results."}, {"generated": ["ventricular tachycardia", "ventricular fibrillation", "arrhythmia", "ventricular precontraction"], "gold": ["arrhythmias", "arrhythmia", "ventricular precontraction, ventricular tachycardia,", "ventricular arrhythmias", "ventricular fibrillation"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["ventricular tachycardia", "ventricular fibrillation", "arrhythmia", "ventricular precontraction"], "gold": ["arrhythmias", "arrhythmia", "ventricular precontraction, ventricular tachycardia,", "ventricular arrhythmias", "ventricular fibrillation"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["ventricular tachycardia", "ventricular fibrillation", "arrhythmia", "ventricular precontraction"], "gold": ["arrhythmias", "arrhythmia", "ventricular precontraction, ventricular tachycardia,", "ventricular arrhythmias", "ventricular fibrillation"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": [], "gold": ["hypertension"], "text": "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy."}, {"generated": ["nausea", "liver damage", "dyslipidemia", "fever", "vomiting", "headache", "diarrhoea"], "gold": ["side effects", "liver damage", "nausea", "dyslipidemia", "fever", "vomiting", "headache", "diarrhoea"], "text": "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10]."}, {"generated": ["adverse side effects from taking G. kola seeds"], "gold": ["Pregnancy", "hypersensitivity", "adverse side effects", "breastfeeding"], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["adverse side effects from taking G. kola seeds"], "gold": ["Pregnancy", "hypersensitivity", "adverse side effects", "breastfeeding"], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["adverse side effects from taking G. kola seeds"], "gold": ["Pregnancy", "hypersensitivity", "adverse side effects", "breastfeeding"], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["adverse side effects from taking G. kola seeds"], "gold": ["Pregnancy", "hypersensitivity", "adverse side effects", "breastfeeding"], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": [], "gold": ["healthy"], "text": "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol."}, {"generated": ["dizziness"], "gold": ["light dizziness"], "text": "Precisely, only 3 participants complained of very light dizziness."}, {"generated": [], "gold": ["HIV positive"], "text": "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11]."}, {"generated": ["positron emission tomography positive residual tumor"], "gold": ["tumor"], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["anticancer drugs", "adverse interactions"], "gold": ["cancer patients"], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["radiological abnormalities", "left ventricular ejection fraction (LVEF)"], "gold": ["the radiological abnormalities"], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": [], "gold": ["menopausal symptoms"], "text": "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["uncontrolled thyroid", "drug or alcohol abuse", "surgery", "menopause", "diabetes", "thromboembolism", "cerebrovascular disease", "hysterectomy", "uterine bleeding", "endometrial hyperplasia", "uncontrolled diabetes mellitus", "cardiovascular disease", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "hypersensitivity", "menopausal", "severe migraines"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["adverse reactions", "degree and result of the adverse reaction"], "gold": ["adverse reactions", "adverse reaction"], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["severe adverse reactions"], "gold": ["adverse reactions"], "text": "It is noteworthy that no severe adverse reactions were observed in this study."}, {"generated": ["large-scale menopausal subjects"], "gold": ["menopausal"], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": [], "gold": ["chronic liver disease"], "text": "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8]."}, {"generated": ["PCOS"], "gold": ["PCOS", "Oxidative stress"], "text": "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3]."}, {"generated": ["PCOS (Polycystic Ovary Syndrome)"], "gold": ["PCOS", "side effects"], "text": "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13]."}, {"generated": ["PCOS (Polycystic Ovary Syndrome)"], "gold": ["PCOS", "side effects"], "text": "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13]."}, {"generated": [], "gold": ["OS"], "text": "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18]."}, {"generated": [], "gold": ["PCOS"], "text": "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up."}, {"generated": ["HIV strains"], "gold": ["AIDS", "HIV"], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["HIV strains"], "gold": ["AIDS", "HIV"], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["HIV-1 RNA load"], "gold": ["adverse events", "patient"], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": ["HIV-1 RNA load"], "gold": ["adverse events", "patient"], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": [], "gold": ["disorders"], "text": "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders."}, {"generated": ["disseminated intravascular coagulation (DIC)", "pathologic inhibitors of coagulation", "coagulopathy of unknown origin", "vitamin K malabsorption"], "gold": ["coagulopathy", "pathologic inhibitors of coagulation", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption"], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": [], "gold": ["adverse events"], "text": "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable."}, {"generated": ["antiepileptic therapy"], "gold": ["Patients"], "text": "Patients on antiepileptic therapy are usually on a long-term basis."}, {"generated": [], "gold": ["diabetes"], "text": "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions."}, {"generated": ["hepatocellular carcinoma"], "gold": ["carcinoma"], "text": "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7]."}, {"generated": ["AZ-AhR cells", "HEK-OATP1B1 cells", "P388/dx cells", "MDCKII-BCRP cells", "HEK-OATP1B3 cells", "P388"], "gold": ["Cancer"], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["cancer therapies"], "gold": ["cancer"], "text": "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies."}, {"generated": ["clinical outcomes", "beneficial interactions", "harmful interactions", "mechanistic explanations"], "gold": ["cancer"], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["platelets", "T cell apoptosis", "WBC (CD3+, CD4+ T cells, NK cells)", "caspase 3 activity", "intestinal damage caused by 5-FU"], "gold": ["metastasis", "intestinal damage"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["tumor recurrence", "metastasis"], "gold": ["metastasis", "tumor"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": ["cytotoxicity", "anticancer drugs", "tumor-infiltrating lymphocytes", "suppressor T cells", "lipid peroxide levels", "superoxide dismutase (SOD)"], "gold": ["cancer"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": ["adverse effects of chemotherapeutic drugs"], "gold": ["adverse effects"], "text": "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings."}, {"generated": ["breast cancer"], "gold": ["cancer", "side effects", "breast cancer"], "text": "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy."}, {"generated": ["breast cancer"], "gold": ["cancer", "side effects", "breast cancer"], "text": "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy."}, {"generated": ["estrogen receptor (ER) positive", "breast tumors"], "gold": ["breast tumors", "ER-positive breast cancer"], "text": "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer."}, {"generated": ["other types of cancer", "breast cancer"], "gold": ["cancer", "breast cancer"], "text": "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313]."}, {"generated": [], "gold": ["diabetic"], "text": "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment."}, {"generated": ["inflammatory response", "oxidative stress", "liver damage", "diabetes"], "gold": ["aberrant inflammatory response", "oxidative stress", "liver damage", "diabetes"], "text": "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response."}, {"generated": ["significantly different from normal group", "significantly different from diabetic control group"], "gold": ["diabetic"], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different from normal group", "significantly different from diabetic control group"], "gold": ["diabetic"], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["indomethacin-induced gastric injury"], "gold": ["gastric injury"], "text": "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert."}, {"generated": ["atrial fibrillation"], "gold": ["bleeding", "atrial fibrillation"], "text": "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5]."}, {"generated": ["prosthetic heart valves", "warfarin"], "gold": ["prosthetic heart"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": [], "gold": ["antihypertensive, antioxidant, and hypocholesterolemic"], "text": "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16]."}, {"generated": [], "gold": ["antioxidant activity"], "text": "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45]."}, {"generated": ["significant increase in total cholesterol"], "gold": ["hypertensive"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": [], "gold": ["hypotensive activity,", "vasodilation"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["hypotensive activity,", "vasodilation"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["cancer cell lines"], "gold": ["anti\u2010cancer activity"], "text": "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines."}, {"generated": [], "gold": ["early stage breast cancer"], "text": "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer."}, {"generated": [], "gold": ["menopause symptoms"], "text": "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines."}, {"generated": ["sexual dysfunction", "cognitive declines", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": ["sexual dysfunction", "cognitive declines", "mood disorders", "weight gain", "night sweats", "menopause", "hot flashes", "sleep disturbances"], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["immunologic disease", "endocrine disease", "hematologic disease", "renal disease", "cardiovascular disease", "pulmonary disease", "gastrointestinal disease", "neurologic disease/disorder", "hepatic disease", "dermatologic disease"], "gold": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["bleeding", "severe fatigue"], "gold": ["bleeding", "severe fatigue", "Fatigue", "ischemic heart disease", "diabetes", "Bleeding", "hypertension"], "text": "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes."}, {"generated": ["bleeding", "severe fatigue"], "gold": ["bleeding", "severe fatigue", "Fatigue", "ischemic heart disease", "diabetes", "Bleeding", "hypertension"], "text": "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes."}, {"generated": ["bleeding", "severe fatigue"], "gold": ["bleeding", "severe fatigue", "Fatigue", "ischemic heart disease", "diabetes", "Bleeding", "hypertension"], "text": "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes."}, {"generated": ["bleeding", "severe fatigue"], "gold": ["bleeding", "severe fatigue", "Fatigue", "ischemic heart disease", "diabetes", "Bleeding", "hypertension"], "text": "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes."}, {"generated": ["drug interactions"], "gold": ["illnesses"], "text": "Drug interactions can be considered illnesses by themselves."}, {"generated": [], "gold": ["cancer"], "text": "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively)."}, {"generated": ["Disease", "side effects", "worse than the disease"], "gold": ["the Disease"], "text": "Worse than the Disease?"}, {"generated": ["rashes caused by Lomatium"], "gold": ["rashes", "the rash"], "text": "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion."}, {"generated": ["rashes caused by Lomatium"], "gold": ["rashes", "the rash"], "text": "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion."}, {"generated": ["pruritis", "rash"], "gold": ["the rash", "pruritis"], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["clinical breast cancer"], "gold": ["breast cancer"], "text": "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions."}, {"generated": ["breast cancer"], "gold": ["cancer", "breast cancer"], "text": "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010)."}, {"generated": ["autophagy", "cell cycle arrest", "apoptosis"], "gold": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"], "text": "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013)."}, {"generated": ["autophagy", "cell cycle arrest", "apoptosis"], "gold": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"], "text": "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013)."}, {"generated": [], "gold": ["anti-proliferative effect", "apoptosis"], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": [], "gold": ["anti-proliferative effect", "apoptosis"], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": [], "gold": ["protective effect"], "text": "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015)."}, {"generated": ["TAM-intoxicated liver injury"], "gold": ["liver injury", "the oxidative stress"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["TAM-intoxicated liver injury"], "gold": ["liver injury", "the oxidative stress"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["healthy"], "text": "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21]."}, {"generated": [], "gold": ["memory loss", "mood disorders", "cardiovascular disorders", "cognition decline", "anxiety", "fatigue"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["memory loss", "mood disorders", "cardiovascular disorders", "cognition decline", "anxiety", "fatigue"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["memory loss", "mood disorders", "cardiovascular disorders", "cognition decline", "anxiety", "fatigue"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["memory loss", "mood disorders", "cardiovascular disorders", "cognition decline", "anxiety", "fatigue"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["memory loss", "mood disorders", "cardiovascular disorders", "cognition decline", "anxiety", "fatigue"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["memory loss", "mood disorders", "cardiovascular disorders", "cognition decline", "anxiety", "fatigue"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["diabetes", "diarrhea"], "text": "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114]."}, {"generated": [], "gold": ["diabetes", "diarrhea"], "text": "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114]."}, {"generated": ["short-term use of opioids"], "gold": ["pain"], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["severe bleeding events"], "gold": ["severe bleeding events", "bleeding risk"], "text": "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication."}, {"generated": ["diabetic treatment"], "gold": ["diabetic"], "text": "This herb has been in use for diabetic treatment for almost two millennia [72]."}, {"generated": [], "gold": ["adverse reactions"], "text": "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions."}, {"generated": [], "gold": ["healthy"], "text": "The in vivo study was conducted on healthy human volunteers."}, {"generated": ["abemaciclib-related diarrhea"], "gold": ["diarrhea"], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}]}